

Adjuvant Chemotherapy in Invasive Bladder Cancer: A Study of Individual Patient Data

European Urology

48, 189-201

DOI: [10.1016/j.eururo.2005.04.005](https://doi.org/10.1016/j.eururo.2005.04.005)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 3 | Adjuvant chemotherapy for bladder cancer. Expert Review of Anticancer Therapy, 2005, 5, 987-991. | 1.1 | 3 |
| 4 | Chemotherapy practices and perspectives in invasive bladder cancer. Expert Review of Anticancer Therapy, 2006, 6, 1473-1482. | 1.1 | 2 |
| 5 | Adjuvant chemotherapy for invasive bladder cancer (individual patient data). The Cochrane Library, 2006, , CD006018. | 1.5 | 34 |
| 7 | Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers. Anti-Cancer Drugs, 2006, 17, 705-708. | 0.7 | 8 |
| 8 | Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU International, 2006, 97, 42-47. | 1.3 | 114 |
| 9 | COMPLETE LONG-TERM SURVIVAL DATA FROM A TRIAL OF ADJUVANT CHEMOTHERAPY VS CONTROL AFTER RADICAL CYSTECTOMY FOR LOCALLY ADVANCED BLADDER CANCER. BJU International, 2006, 97, 1348-1348. | 1.3 | 0 |
| 11 | WHAT HAS BEEN LEARNED FROM META-ANALYSES OF NEOADJUVANT AND ADJUVANT CHEMOTHERAPY IN BLADDER CANCER?. BJU International, 2006, 98, 487-489. | 1.3 | 13 |
| 16 | Re: Complete Long-Term Survival Data from a Trial of Adjuvant Chemotherapy vs Control after Radical Cystectomy for Locally Advanced Bladder Cancer. European Urology, 2006, 49, 1135. | 0.9 | 1 |
| 17 | Re: Complete Long-Term Survival Data from a Trial of Adjuvant Chemotherapy vs Control After Radical Cystectomy for Locally Advanced Bladder Cancer. European Urology, 2006, 50, 616-617. | 0.9 | 0 |
| 18 | Formulas Calculating Creatinine Clearance Are Inadequate for Determining Eligibility for Cisplatin-Based Chemotherapy in Bladder Cancer. Journal of Clinical Oncology, 2006, 24, 3095-3100. | 0.8 | 67 |
| 19 | Developing innovative strategies for advanced transitional cell carcinoma of the bladder. Expert Review of Anticancer Therapy, 2006, 6, 83-92. | 1.1 | 4 |
| 20 | Muscle invasive and metastatic bladder cancer. Annals of Oncology, 2006, 17, x23-x30. | 0.6 | 15 |
| 21 | A case of T2 muscle-invasive bladder cancer treated with neoadjuvant chemotherapy. Nature Reviews Urology, 2006, 3, 675-679. | 1.4 | 0 |
| 22 | Are Nomograms Better Than Currently Available Stage Groupings for Bladder Cancer?. Journal of Clinical Oncology, 2006, 24, 3819-3820. | 0.8 | 152 |
| 23 | Treatment of muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2007, 7, 1279-1283. | 1.1 | 24 |
| 24 | Treatment of muscle-invasive bladder cancer: is cystectomy enough?. Nature Reviews Urology, 2007, 4, 126-127. | 1.4 | 1 |
| 25 | Emerging drugs for targeted therapy of bladder cancer. Expert Opinion on Emerging Drugs, 2007, 12, 435-448. | 1.0 | 7 |
| 26 | Neo-adjuvant and adjuvant chemotherapy in bladder cancer. Annals of Oncology, 2007, 18, vi162-vi163. | 0.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 27 | Bladder Cancer: Epidemiology, Diagnosis, and Treatment. <i>Seminars in Oncology Nursing</i> , 2007, 23, S3-S10. | 0.7 | 3 |
| 28 | Positive Surgical Margins in Soft Tissue Following Radical Cystectomy for Bladder Cancer and Cancer Specific Survival. <i>Journal of Urology</i> , 2007, 178, 2308-2313. | 0.2 | 217 |
| 29 | Harnblasenkarzinom. , 2007, , 301-372. | | 0 |
| 31 | Defining Optimal Therapy for Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2007, 177, 437-443. | 0.2 | 204 |
| 33 | Improving the prognosis of patients after radical cystectomy. Part II: the role of perioperative chemotherapy. <i>BJU International</i> , 2007, 100, 1225-1228. | 1.3 | 8 |
| 34 | Adjuvant Chemotherapy for Bladder Cancer: The Chance for Meta-analyses Comparison. <i>European Urology</i> , 2007, 51, 576-577. | 0.9 | 4 |
| 35 | Re: Emilio Bria, Enzo Maria Ruggeri, Edmondo Terzoli, Francesco Cognetti, Camillo Francesco Pollera and Diana Giannarelli. Adjuvant Chemotherapy for Bladder Cancer: The Chance for Meta-analyses Comparison. <i>Eur Urol</i> 2007;51:576-7. <i>European Urology</i> , 2007, 51, 577-578. | 0.9 | 0 |
| 36 | Perioperative Chemotherapy in Muscle-Invasive Bladder Cancer to Enhance Survival and/or as a Strategy for Bladder Preservation. <i>Seminars in Oncology</i> , 2007, 34, 122-128. | 0.8 | 14 |
| 41 | High-risk bladder cancer: improving outcomes with perioperative chemotherapy. <i>Oncology Reviews</i> , 2008, 2, 4-8. | 0.8 | 0 |
| 42 | Contemporary management of muscle-invasive bladder cancer. <i>International Journal of Clinical Oncology</i> , 2008, 13, 504-509. | 1.0 | 11 |
| 43 | Chimiothérapie néoadjuvante et carcinomes urothéliaux infiltrants de vessie de stade localisé. Des données de la littérature à la pratique quotidienne: it's a long way to go... <i>Oncologie</i> , 2008, 10, 657-660. | 0.2 | 0 |
| 44 | Survival from bladder cancer in England and Wales up to 2001. <i>British Journal of Cancer</i> , 2008, 99, S90-S92. | 2.9 | 11 |
| 45 | Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. <i>BJU International</i> , 2008, 101, 1356-1361. | 1.3 | 19 |
| 46 | Laparoscopic radical cystectomy for muscle-invasive bladder cancer: pathological and oncological outcomes. <i>BJU International</i> , 2008, 102, 1296-1301. | 1.3 | 29 |
| 47 | Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. <i>BJU International</i> , 2008, 102, 1339-1344. | 1.3 | 17 |
| 48 | Urothelial Carcinoma of the Upper Urinary Tract: Surgical Approach and Prognostic Factors. <i>European Urology</i> , 2008, 53, 720-731. | 0.9 | 153 |
| 49 | The Motion: Perioperative Chemotherapy in Muscle Invasive Bladder Cancer Improves Survival. <i>European Urology</i> , 2008, 54, 1192-1197. | 0.9 | 4 |
| 50 | Misconceptions, Challenges, Uncertainty, and Progress in Guideline Recommendations. <i>Seminars in Hematology</i> , 2008, 45, 167-175. | 1.8 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 52 | Radical Cystectomy for Carcinoma of the Bladder: 2,720 Consecutive Cases 5 Years Later. <i>Journal of Urology</i> , 2008, 180, 121-127. | 0.2 | 263 |
| 53 | Neoadjuvant chemotherapy preceding cystectomy for bladder cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1885-1893. | 0.9 | 3 |
| 54 | Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder. <i>Acta Oncologica</i> , 2008, 47, 937-940. | 0.8 | 8 |
| 55 | Management of muscle-invasive bladder cancer: an update. <i>Nature Reviews Urology</i> , 2008, 5, 501-508. | 1.4 | 25 |
| 56 | Neoadjuvant chemotherapy for the treatment of muscle-invasive bladder cancer: argument in favor. <i>Nature Reviews Urology</i> , 2008, 5, 484-485. | 1.4 | 12 |
| 57 | Risk factors and clinical outcomes of patients with node-positive muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1091-1101. | 1.1 | 13 |
| 58 | The chemotherapeutic management of bladder cancer. , 2008, , 125-136. | | 0 |
| 59 | Bladder. , 0, , 222-230. | | 0 |
| 60 | Vinflunine in the treatment of bladder cancer. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 1243-1253. | 0.9 | 12 |
| 61 | Neurofuzzy Modeling to Determine Recurrence Risk Following Radical Cystectomy for Nonmetastatic Urothelial Carcinoma of the Bladder. <i>Clinical Cancer Research</i> , 2009, 15, 3150-3155. | 3.2 | 24 |
| 62 | Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 821-830. | 1.1 | 19 |
| 63 | Grade and Stage at Presentation Do Not Predict Mortality in Patients With Bladder Cancer Who Survive Their Disease. <i>Journal of Clinical Oncology</i> , 2009, 27, 2443-2449. | 0.8 | 16 |
| 64 | La integraci3n de la cirugÃa y el tratamiento quimioterÃpico en el cÃncer de vejiga infiltrante. <i>Actas Urol3gicas EspaÃolas</i> , 2009, 33, 1062-1068. | 0.3 | 3 |
| 65 | Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2009, 55, 348-358. | 0.9 | 79 |
| 66 | The Updated EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer. <i>European Urology</i> , 2009, 55, 815-825. | 0.9 | 316 |
| 67 | Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma. <i>Cancer</i> , 2009, 115, 5193-5201. | 2.0 | 13 |
| 68 | Clinical benefits of a multivariate prediction model for bladder cancer. <i>Cancer</i> , 2009, 115, 5460-5469. | 2.0 | 32 |
| 69 | Quantitative risk stratification and individual comprehensive therapy for invasive bladder cancers in China. <i>International Urology and Nephrology</i> , 2009, 41, 571-577. | 0.6 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-------|-----------|
| 70 | The Role and Extent of Pelvic Lymphadenectomy in the Management of Patients with Invasive Urothelial Carcinoma. <i>Current Treatment Options in Oncology</i> , 2009, 10, 267-274. | 1.3 | 10 |
| 71 | Bladder Cancer. <i>Current Treatment Options in Oncology</i> , 2009, 10, 205-215. | 1.3 | 32 |
| 74 | Neoadjuvant systemic therapy for urological malignancies. <i>BJU International</i> , 2010, 106, 6-22. | 1.3 | 22 |
| 75 | Adjuvant chemotherapy in lymph node positive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 160-164. | 0.8 | 17 |
| 76 | Bladder cancer in the elderly. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 653-667. | 0.8 | 174 |
| 77 | Management of Bladder Cancer. <i>Drugs</i> , 2009, 69, 1173-1187. | 4.9 | 15 |
| 78 | Harnblasenkarzinom. , 2009, , 395-476. | | 1 |
| 79 | Bladder cancer. <i>Lancet, The</i> , 2009, 374, 239-249. | 6.3 | 959 |
| 80 | Opposing Views. <i>Journal of Urology</i> , 2009, 181, 1994-1997. | 0.2 | 14 |
| 81 | The effect of age on bladder cancer incidence, prognosis and therapy. <i>Aging Health</i> , 2010, 6, 649-659. | 0.3 | 7 |
| 85 | The role of adjuvant chemotherapy in patients with locally advanced (pT3, pT4a) and/or lymph nodeâ€“positive bladder cancer. <i>International Urology and Nephrology</i> , 2010, 42, 959-964. | 0.6 | 2 |
| 86 | Bladder Cancer in 2010: How Far have We Come?. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 244-272. | 157.7 | 291 |
| 90 | Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. <i>Cancer</i> , 2010, 116, 2967-2973. | 2.0 | 178 |
| 91 | Risk factors for recurrence following radical cystectomy for pathologic node negative bladder cancer. <i>Journal of Surgical Oncology</i> , 2010, 102, 334-337. | 0.8 | 13 |
| 92 | The effect of age and gender on bladder cancer: a critical review of the literature. <i>BJU International</i> , 2010, 105, 300-308. | 1.3 | 281 |
| 93 | Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph nodeâ€“negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. <i>BJU International</i> , 2010, 106, 493-499. | 1.3 | 61 |
| 94 | New Italian guidelines on bladder cancer, based on the World Health Organization 2004 classification. <i>BJU International</i> , 2010, 106, 168-179. | 1.3 | 8 |
| 95 | Evidenceâ€“based clinical practice guidelines for bladder cancer (Summary â€“ JUA 2009 Edition). <i>International Journal of Urology</i> , 2010, 17, 102-124. | 0.5 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 96 | Management of renal and bladder cancer in older adults. , 0, , 171-185. | | 0 |
| 98 | Pattern of Failure in Bladder Cancer Patients Treated with Radical Cystectomy: Rationale for Adjuvant Radiotherapy. Journal of Korean Medical Science, 2010, 25, 835. | 1.1 | 4 |
| 99 | The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder. Clinical Cancer Research, 2010, 16, 4461-4467. | 3.2 | 133 |
| 100 | Bladder cancer. Current Opinion in Oncology, 2010, 22, 242-249. | 1.1 | 32 |
| 101 | Outcome of Surgical Treatment of Patients with Upper versus Lower Urinary Tract Urothelial Carcinoma: Stage-by-Stage Comparison. Urologia Internationalis, 2010, 84, 50-55. | 0.6 | 25 |
| 102 | Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v134-v136. | 0.6 | 19 |
| 103 | Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma. Actas Urológicas Españolas (English Edition), 2010, 34, 51-62. | 0.2 | 5 |
| 105 | Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nature Reviews Urology, 2011, 8, 631-642. | 1.9 | 123 |
| 107 | Disease-Free Survival at 2 or 3 Years Correlates With 5-Year Overall Survival of Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. Journal of Urology, 2011, 185, 456-461. | 0.2 | 86 |
| 109 | A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. Journal of Clinical Epidemiology, 2011, 64, 949-967. | 2.4 | 150 |
| 110 | Outcomes of Single Lymph Node Positive Urothelial Carcinoma After Radical Cystectomy. Journal of Urology, 2011, 185, 2085-2090. | 0.2 | 20 |
| 111 | Review of Current Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. European Urology Supplements, 2011, 10, e20-e25. | 0.1 | 4 |
| 112 | Current therapeutic strategies for invasive and metastatic bladder cancer. OncoTargets and Therapy, 2011, 4, 97. | 1.0 | 33 |
| 113 | Update on Chemotherapy in the Treatment of Urothelial Carcinoma. Scientific World Journal, The, 2011, 11, 1981-1994. | 0.8 | 22 |
| 114 | Bladder cancer. Current Opinion in Oncology, 2011, 23, 275-282. | 1.1 | 40 |
| 115 | Management of elderly patients with advanced infiltrating and metastatic bladder cancer: an oncogeriatric approach. Aging Health, 2011, 7, 491-502. | 0.3 | 0 |
| 116 | Induction chemotherapy for unresectable urothelial carcinoma of the bladder. BJU International, 2011, 107, 894-897. | 1.3 | 23 |
| 117 | Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU International, 2011, 108, 539-545. | 1.3 | 156 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 118 | Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. <i>European Urology</i> , 2011, 59, 1009-1018. | 0.9 | 570 |
| 119 | SEOM clinical guidelines for the treatment of invasive bladder cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 552-559. | 1.2 | 6 |
| 120 | Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?. <i>Oncology Reviews</i> , 2011, 5, 185-189. | 0.8 | 1 |
| 121 | Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Qstatistics. <i>BMC Medical Research Methodology</i> , 2011, 11, 41. | 1.4 | 384 |
| 122 | Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. <i>Cancer</i> , 2011, 117, 1190-1196. | 2.0 | 29 |
| 123 | Diagnosis and Management of Urothelial Carcinoma of the Bladder. <i>Postgraduate Medicine</i> , 2011, 123, 43-55. | 0.9 | 33 |
| 124 | Role of chemotherapy in upper urinary tract urothelial cell cancers. <i>Future Oncology</i> , 2011, 7, 1067-1075. | 1.1 | 0 |
| 125 | Standardizing the care of invasive bladder cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 454-455. | 12.5 | 3 |
| 126 | CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. <i>Expert Review of Vaccines</i> , 2011, 10, 733-742. | 2.0 | 36 |
| 127 | Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2011, 22, vi45-vi49. | 0.6 | 94 |
| 128 | Are we undertreating invasive bladder cancer? Optimizing outcomes in a high-risk disease. <i>Current Opinion in Supportive and Palliative Care</i> , 2011, 5, 192-198. | 0.5 | 0 |
| 129 | Kuhn's Paradigms: Are Those Closest to Treating Bladder Cancer the Last to Appreciate the Paradigm Shift?. <i>Journal of Clinical Oncology</i> , 2011, 29, 2135-2137. | 0.8 | 27 |
| 130 | New Strategies in Muscle-Invasive Bladder Cancer: On the Road to Personalized Medicine. <i>Clinical Cancer Research</i> , 2011, 17, 2608-2612. | 3.2 | 96 |
| 131 | International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2171-2177. | 0.8 | 804 |
| 132 | Low ANXA10 expression is associated with disease aggressiveness in bladder cancer. <i>British Journal of Cancer</i> , 2011, 105, 1379-1387. | 2.9 | 41 |
| 133 | Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives. <i>Cancers</i> , 2011, 3, 3055-3072. | 1.7 | 25 |
| 134 | Progress in Personalizing Chemotherapy for Bladder Cancer. <i>Advances in Urology</i> , 2012, 2012, 1-10. | 0.6 | 23 |
| 135 | Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. <i>Annals of Oncology</i> , 2012, 23, 695-700. | 0.6 | 182 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 136 | Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder. <i>Current Opinion in Oncology</i> , 2012, 24, 278-283. | 1.1 | 7 |
| 137 | Chemotherapy for bladder cancer in patients with impaired renal function. <i>Nature Reviews Urology</i> , 2012, 9, 52-57. | 1.9 | 16 |
| 138 | Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. <i>British Journal of Cancer</i> , 2012, 107, 1826-1832. | 2.9 | 34 |
| 139 | New Directions for Biologic Targets in Urothelial Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1226-1235. | 1.9 | 14 |
| 141 | A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2012, 62, 523-533. | 0.9 | 214 |
| 142 | Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: Summary of session at the Society of Urologic Oncology annual meeting. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 772-780. | 0.8 | 33 |
| 145 | Efficacy of Adjuvant Chemotherapy after Surgery when Considered over all Cancer Types: A Synthesis of Meta-Analyses. <i>Annals of Surgical Oncology</i> , 2012, 19, 3343-3350. | 0.7 | 10 |
| 146 | Relative Efficacy of Perioperative Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Adriamycin, and Cisplatin in the Management of Locally Advanced Urothelial Carcinoma of the Bladder. <i>Urology</i> , 2012, 79, 384-390. | 0.5 | 62 |
| 148 | Recommendations for the optimal management of early and advanced urothelial carcinoma. <i>Cancer Treatment Reviews</i> , 2012, 38, 431-441. | 3.4 | 12 |
| 149 | ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy. <i>BMC Cancer</i> , 2012, 12, 187. | 1.1 | 35 |
| 150 | Is Adjunctive Systemic Chemotherapy After Cystectomy for T2N+ Disease of Therapeutic Benefit?. <i>Journal of Urology</i> , 2012, 188, 358-360. | 0.2 | 3 |
| 151 | Surgical and Chemotherapeutic Management of Regional Lymph Nodes in Bladder Cancer. <i>Journal of Urology</i> , 2012, 188, 1081-1088. | 0.2 | 19 |
| 152 | Molecular mechanisms of cisplatin resistance in bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 271-281. | 1.1 | 92 |
| 154 | Treatment of muscle-invasive and metastatic bladder cancer: Update of the EAU guidelines. <i>Actas Urológicas Españolas (English Edition)</i> , 2012, 36, 449-460. | 0.2 | 9 |
| 155 | Update on the management of invasive bladder cancer 2012. <i>Cancer Management and Research</i> , 2012, 4, 177. | 0.9 | 3 |
| 156 | Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. <i>Cancer</i> , 2012, 118, 3920-3927. | 2.0 | 40 |
| 159 | Current chemotherapeutic strategies against bladder cancer. <i>International Urology and Nephrology</i> , 2012, 44, 431-441. | 0.6 | 7 |
| 160 | Neoadjuvant and adjuvant chemotherapy for locally advanced bladder carcinoma: Development of novel bladder preservation approach, Osaka Medical College regimen. <i>International Journal of Urology</i> , 2012, 19, 26-38. | 0.5 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 161 | Impact of the CKD-EPI Equation for Estimating Renal Function on Eligibility for Cisplatin-based Chemotherapy in Patients With Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 15-20. | 0.9 | 38 |
| 162 | Intensity-Modulated and Image-Guided Radiation Therapy for Treatment of Genitourinary Carcinomas in Dogs. <i>Journal of Veterinary Internal Medicine</i> , 2012, 26, 987-995. | 0.6 | 71 |
| 163 | Perivesical fat invasion in bladder cancer: implications for prognosis comparing pT2b, pT3a and pT3b stages and consequences for adjuvant chemotherapy indications. <i>BJU International</i> , 2012, 110, 1736-1741. | 1.3 | 21 |
| 165 | Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. <i>BMC Cancer</i> , 2013, 13, 71. | 1.1 | 74 |
| 166 | SNAI1 Protein Expression is an Independent Negative Prognosticator in Muscle-Invasive Bladder Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 3669-3674. | 0.7 | 11 |
| 167 | Oncologic outcomes obtained after neoadjuvant and adjuvant chemotherapy for the treatment of urothelial carcinomas of the upper urinary tract: a review. <i>World Journal of Urology</i> , 2013, 31, 77-82. | 1.2 | 20 |
| 168 | Comprehensive handbook for developing a bladder cancer cystectomy database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 812-826. | 0.8 | 7 |
| 170 | Tailored Treatment for Bladder Cancer in Older Patients. , 2013, , 271-279. | | 0 |
| 171 | Understanding Avoidance, Refusal, and Abandonment of Chemotherapy Before and After Cystectomy for Bladder Cancer. <i>Urology</i> , 2013, 82, 1370-1375. | 0.5 | 30 |
| 173 | Lymph node-positive bladder cancer: surgical, pathologic, molecular and prognostic aspects. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1281-1295. | 1.1 | 13 |
| 174 | Neoadjuvant chemotherapy in muscle-invasive bladder cancer: Ready for prime time?. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 288-294. | 2.0 | 4 |
| 175 | Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networks. <i>European Journal of Surgical Oncology</i> , 2013, 39, 372-379. | 0.5 | 20 |
| 176 | Bladder Cancer Imaging. , 2013, , 65-93. | | 0 |
| 177 | Multidisciplinary Management of Patients with Localized Bladder Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 357-373. | 0.6 | 2 |
| 178 | External Validation of Extranodal Extension and Lymph Node Density as Predictors of Survival in Node-positive Bladder Cancer after Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2013, 20, 1389-1394. | 0.7 | 31 |
| 179 | Risk Group Stratification Based on Preoperative Factors to Predict Survival after Nephroureterectomy in Patients with Upper Urinary Tract Urothelial Carcinoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 4389-4396. | 0.7 | 35 |
| 180 | Can trial quality be reliably assessed from published reports of cancer trials: evaluation of risk of bias assessments in systematic reviews. <i>BMJ, The</i> , 2013, 346, f1798-f1798. | 3.0 | 43 |
| 181 | Neoadjuvant Paradigm for Accelerated Drug Development: An Ideal Model in Bladder Cancer. <i>Oncologist</i> , 2013, 18, 933-940. | 1.9 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 182 | Neoadjuvant chemotherapy (NC) should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer (MIUC) of the bladder – A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. Canadian Urological Association Journal, 2013, 7, 312. | 0.3 | 18 |
| 183 | Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal health care system. Canadian Urological Association Journal, 2013, 7, 667. | 0.3 | 6 |
| 184 | ¹⁸ ^F fluorodeoxyglucose positron emission tomography – computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: A prospective study. International Journal of Urology, 2013, 20, 788-796. | 0.5 | 43 |
| 185 | Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephroureterectomy. BJU International, 2013, 112, 453-461. | 1.3 | 128 |
| 186 | Radio-chemotherapy for bladder cancer: Contribution of chemotherapy on local control. World Journal of Radiology, 2013, 5, 267. | 0.5 | 11 |
| 187 | New therapeutic targets in the management of urothelial carcinoma of the bladder. Research and Reports in Urology, 2013, 5, 53. | 0.6 | 5 |
| 188 | The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma. Journal of Cancer, 2013, 4, 686-690. | 1.2 | 36 |
| 189 | Optimizing care and outcomes of patients with muscle-invasive bladder cancer. Canadian Urological Association Journal, 2013, 7, 625. | 0.3 | 1 |
| 190 | Radical cystectomy is the treatment of choice for invasive bladder cancer. Canadian Urological Association Journal, 2013, 3, 409. | 0.3 | 10 |
| 191 | Perioperative chemotherapy for muscle-invasive bladder cancer. Canadian Urological Association Journal, 2013, 3, 223. | 0.3 | 7 |
| 192 | Perioperative chemotherapy: the case for adjuvant chemotherapy for muscle-invasive bladder cancer. Canadian Urological Association Journal, 2013, 2, 225. | 0.3 | 2 |
| 193 | A case of isolated rectal recurrence of muscle invasive bladder cancer. Canadian Urological Association Journal, 2013, 7, 376. | 0.3 | 1 |
| 194 | Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy. Drug Design, Development and Therapy, 2014, 8, 1985. | 2.0 | 7 |
| 195 | Systemic therapy for bladder cancer – a medical oncologist’s perspective. Journal of Solid Tumors, 2014, 4, 25-35. | 0.1 | 14 |
| 197 | Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer, 2014, 14, 966. | 1.1 | 24 |
| 198 | Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice. Annals of Oncology, 2014, 25, 1783-1788. | 0.6 | 32 |
| 199 | Ureterocutaneostomy: for whom and when?. Turk Uroloji Dergisi, 2014, 39, 143-146. | 0.4 | 9 |
| 200 | Bladder Cancer in Males: A Comprehensive Review of Urothelial Carcinoma of the Bladder. Journal of Men's Health, 2014, 11, 18-27. | 0.1 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 201 | Sunitinib malate in the treatment of urothelial cancer. Expert Opinion on Investigational Drugs, 2014, 23, 115-124. | 1.9 | 4 |
| 202 | Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives. Expert Review of Anticancer Therapy, 2014, 14, 1429-1443. | 1.1 | 1 |
| 203 | Serum total hCG ^{β2} level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract. British Journal of Cancer, 2014, 110, 1759-1766. | 2.9 | 30 |
| 205 | <sc>IJU</sc> this issue. International Journal of Urology, 2014, 21, 441-441. | 0.5 | 24 |
| 206 | Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study. Cancer, 2014, 120, 1630-1638. | 2.0 | 83 |
| 207 | Template-based lymphadenectomy in urothelial carcinoma of the renal pelvis: A prospective study. International Journal of Urology, 2014, 21, 453-459. | 0.5 | 48 |
| 208 | Patterns of referral for perioperative chemotherapy among patients with muscle-invasive bladder cancer: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1200-1208. | 0.8 | 29 |
| 209 | Influence of Histologic Criteria and Confounding Factors in Staging Equivocal Cases for Microscopic Perivesical Tissue Invasion (pT3a). American Journal of Surgical Pathology, 2014, 38, 167-175. | 2.1 | 16 |
| 210 | Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, iii40-iii48. | 0.6 | 278 |
| 211 | Adjuvant chemotherapy for bladder cancer—why does level 1 evidence not support it?. Annals of Oncology, 2014, 25, 1930-1934. | 0.6 | 20 |
| 212 | Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials. European Urology, 2014, 66, 42-54. | 0.9 | 349 |
| 213 | Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: Assessment of adequate renal function and influence on outcome. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 31.e17-31.e24. | 0.8 | 49 |
| 214 | Adjuvant chemotherapy is associated with decreased mortality after radical cystectomy for locally advanced bladder cancer. World Journal of Urology, 2014, 32, 1463-1468. | 1.2 | 6 |
| 215 | EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines. European Urology, 2014, 65, 778-792. | 0.9 | 868 |
| 216 | The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 806-814. | 0.8 | 78 |
| 217 | Multimodal management of muscle-invasive bladder cancer. Current Problems in Cancer, 2014, 38, 80-108. | 1.0 | 76 |
| 218 | Why is perioperative chemotherapy for bladder cancer underutilized?. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 391-395. | 0.8 | 15 |
| 219 | Pathological T0 Following Radical Cystectomy with or without Neoadjuvant Chemotherapy: A Useful Surrogate. Journal of Urology, 2014, 191, 898-906. | 0.2 | 51 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 220 | Thoughts on a Systematic Review and Meta-analysis of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2014, 66, 55-56. | 0.9 | 14 |
| 221 | Association of Oncofetal Protein Expression with Clinical Outcomes in Patients with Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2014, 191, 830-841. | 0.2 | 19 |
| 222 | T2 Muscle-Invasive Bladder Cancer. <i>Seminars in Oncology</i> , 2014, 41, e11-e18. | 0.8 | 0 |
| 223 | Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients. <i>International Journal of Cancer</i> , 2015, 136, 443-451. | 2.3 | 41 |
| 224 | Perioperative chemotherapy for muscle invasive bladder cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2015, 9, 249-254. | 0.5 | 1 |
| 225 | Management of muscle-invasive bladder cancer in the elderly. <i>Current Opinion in Urology</i> , 2015, 25, 459-467. | 0.9 | 14 |
| 226 | External validation of FXD3 and KRT20 as predictive biomarkers for the presence of micrometastasis in muscle invasive bladder cancer lymph nodes. <i>Actas Urológicas Españolas (English Edition)</i> , 2015, 39, 473-481. | 0.2 | 4 |
| 227 | Chemotherapy for Invasive Bladder Cancer: Five Simple Rules Learned Over 30 Years. <i>Bladder Cancer</i> , 2015, 1, 3-13. | 0.2 | 9 |
| 228 | Pathological factors associated with survival benefit from adjuvant chemotherapy (<sc>ACT</sc>): a population-based study of bladder cancer. <i>BJU International</i> , 2015, 116, 373-381. | 1.3 | 8 |
| 229 | Adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: updated results of the Seoul National university hospital experience. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2015, 41, 1067-1079. | 0.7 | 15 |
| 230 | The Role of Population-Based Observational Research in Bladder Cancer. <i>Bladder Cancer</i> , 2015, 1, 123-131. | 0.2 | 1 |
| 231 | Disease-Free Survival at 2 and 3 Years is a Significant Early Surrogate Marker Predicting the 5-Year Overall Survival in Patients Treated with Radical Cystectomy for Urothelial Carcinoma of the Bladder: External Evaluation and Validation in a Cohort of Korean Patients. <i>Frontiers in Oncology</i> , 2015, 5, 246. | 1.3 | 10 |
| 232 | Diagnosis of Bladder Carcinoma. <i>Surgical Pathology Clinics</i> , 2015, 8, 677-685. | 0.7 | 17 |
| 234 | Comment re: Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3â€“pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC Tj ETQq1 1 0,784314,rgBT /Oncology. <i>Urology</i> , 2015, 68, 1104-1105. | 0.9 | 10 |
| 235 | Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3â€“pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 76-86. | 5.1 | 323 |
| 236 | Bladder Preservation Strategies. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 289-300. | 0.9 | 10 |
| 237 | Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 731-742. | 1.5 | 14 |
| 238 | Three-tiered nodal classification system for bladder cancer: a new proposal. <i>Future Oncology</i> , 2015, 11, 399-408. | 1.1 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 239 | Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy. <i>World Journal of Urology</i> , 2015, 33, 1087-1093. | 1.2 | 20 |
| 240 | Benefits of Adjuvant Chemotherapy for Bladder Cancer. <i>JAMA Oncology</i> , 2015, 1, 727. | 3.4 | 12 |
| 241 | How individual participant data meta-analyses have influenced trial design, conduct, and analysis. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 1325-1335. | 2.4 | 60 |
| 242 | Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer. <i>Urologic Clinics of North America</i> , 2015, 42, 217-224. | 0.8 | 9 |
| 243 | Adjuvant chemotherapy after radical cystectomy for bladder cancer: a comparative study using inverse-probability-of-treatment weighting. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 169-176. | 1.2 | 16 |
| 244 | Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 387-396. | 2.0 | 100 |
| 245 | Perioperative Therapy for Muscle Invasive Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 301-318. | 0.9 | 5 |
| 246 | Opportunities to improve clinical trial design in urothelial bladder cancer. <i>Clinical Research and Regulatory Affairs</i> , 2015, 32, 61-69. | 2.1 | 0 |
| 247 | Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 963-967. | 0.6 | 1 |
| 248 | Validación externa de los ARNm: FXYD3 y KRT20 como biomarcadores predictivos de la presencia de micrometástasis en ganglios de pacientes con tumor vesical infiltrante. <i>Actas Urológicas Españolas</i> , 2015, 39, 473-481. | 0.3 | 6 |
| 249 | Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 293-316. | 0.8 | 7 |
| 250 | Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-invasive Bladder Cancer: A Sign of Changing Tides. <i>European Urology</i> , 2015, 67, 165-170. | 0.9 | 196 |
| 251 | An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer. <i>Biomolecules</i> , 2016, 6, 37. | 1.8 | 44 |
| 252 | NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1213-1224. | 2.3 | 93 |
| 253 | Cáncer de vejiga: diagnóstico y principios terapéuticos. <i>EMC - Urología</i> , 2016, 48, 1-17. | 0.0 | 1 |
| 254 | Re: Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. <i>European Urology</i> , 2016, 70, 204. | 0.9 | 0 |
| 255 | Urothelial carcinoma management in elderly or unfit patients. <i>European Journal of Cancer, Supplement</i> , 2016, 14, 1-20. | 2.2 | 45 |
| 256 | Adjuvant Chemotherapy Is More Suitable Than Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer Patients Treated With Radical Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 614-616. | 0.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 257 | The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. <i>Cancer</i> , 2016, 122, 712-721. | 2.0 | 25 |
| 258 | Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises. <i>Future Oncology</i> , 2016, 12, 2049-2058. | 1.1 | 8 |
| 259 | Bladder cancer. <i>Lancet, The</i> , 2016, 388, 2796-2810. | 6.3 | 1,031 |
| 260 | Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. <i>Journal of Clinical Oncology</i> , 2016, 34, 2627-2635. | 0.8 | 69 |
| 261 | Chemotherapy for Muscle-Invasive Bladder Cancer: Better Late Than Never?. <i>Journal of Clinical Oncology</i> , 2016, 34, 780-785. | 0.8 | 8 |
| 262 | Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 825-832. | 0.8 | 158 |
| 264 | Improving Systemic Chemotherapy for Bladder Cancer. <i>Current Oncology Reports</i> , 2016, 18, 27. | 1.8 | 42 |
| 265 | A Review of Neoadjuvant and Adjuvant Chemotherapy for Nonmetastatic Muscle Invasive Bladder Cancer. <i>Urology Practice</i> , 2016, 3, 41-49. | 0.2 | 0 |
| 266 | Chemotherapy for Muscle-Invasive Bladder Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 6. | 1.3 | 19 |
| 267 | Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit. <i>World Journal of Urology</i> , 2016, 34, 3-11. | 1.2 | 21 |
| 269 | Robotic assisted laparoscopic radical cystectomy with stentless intracorporeal modified Ves.Pa neobladder: early experience. <i>Journal of Robotic Surgery</i> , 2017, 11, 423-431. | 1.0 | 4 |
| 270 | Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer. <i>Oncolmmunology</i> , 2017, 6, e1293211. | 2.1 | 57 |
| 272 | Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?. <i>ESMO Open</i> , 2017, 2, e000123. | 2.0 | 5 |
| 274 | Preoperative determinant of early postoperative renal function following radical cystectomy and intestinal urinary diversion. <i>International Urology and Nephrology</i> , 2017, 49, 233-238. | 0.6 | 10 |
| 275 | Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer. <i>Medical Oncology</i> , 2017, 34, 170. | 1.2 | 31 |
| 277 | Landmarks in the treatment of muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2017, 14, 565-574. | 1.9 | 122 |
| 278 | Urothelial Tumors. , 2017, , 59-93. | | 0 |
| 279 | Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e45-e52. | 0.9 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 280 | Cost of illness of urothelial bladder cancer in Italy. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 433-442. | 0.7 | 15 |
| 281 | Systemic Chemotherapy in Muscle Invasive and Metastatic Bladder Cancer: Present and Future. Urologia, 2017, 84, 130-141. | 0.3 | 8 |
| 282 | Perioperative chemotherapy for bladder cancer: A qualitative study of physician knowledge, attitudes, and behaviour. Canadian Urological Association Journal, 2017, 12, E182-90. | 0.3 | 1 |
| 283 | Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials. Oncotarget, 2017, 8, 81204-81214. | 0.8 | 23 |
| 286 | Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma. Urologic Clinics of North America, 2018, 45, 155-167. | 0.8 | 14 |
| 287 | Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 413-422. | 0.8 | 32 |
| 288 | Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. Oncotarget, 2018, 9, 18797-18810. | 0.8 | 10 |
| 290 | Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer. Oncoimmunology, 2018, 7, e1474317. | 2.1 | 61 |
| 291 | The latest treatment options for bladder cancer. British Medical Bulletin, 2018, 128, 85-95. | 2.7 | 33 |
| 292 | Lymphovascular invasion have a similar prognostic value as lymph node involvement in patients undergoing radical cystectomy with urothelial carcinoma. Scientific Reports, 2018, 8, 15928. | 1.6 | 9 |
| 293 | Genitourinary Pathology Reporting Parameters Most Relevant to the Medical Oncologist. Surgical Pathology Clinics, 2018, 11, 877-891. | 0.7 | 0 |
| 294 | Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma. Current Treatment Options in Oncology, 2018, 19, 36. | 1.3 | 22 |
| 295 | Adjuvant Chemotherapy. , 2018, , 451-466. | | 2 |
| 296 | Molecularly-driven precision medicine for advanced bladder cancer. World Journal of Urology, 2018, 36, 1749-1757. | 1.2 | 4 |
| 297 | Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers. Bladder Cancer, 2018, 4, 49-65. | 0.2 | 8 |
| 298 | Propensity-matched analysis of stage-specific efficacy of adjuvant chemotherapy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 877-885. | 0.8 | 3 |
| 299 | Estimating the optimal perioperative chemotherapy utilization rate for muscle-invasive bladder cancer. Cancer Medicine, 2019, 8, 6258-6271. | 1.3 | 6 |
| 300 | Radical Cystectomy. , 2019, , 69-113. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 301 | The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG). Targeted Oncology, 2019, 14, 15-32. | 1.7 | 12 |
| 302 | Organ preservation in bladder cancer: an opportunity for truly personalized treatment. Nature Reviews Urology, 2019, 16, 511-522. | 1.9 | 31 |
| 303 | Role of adjuvant cisplatin-based chemotherapy following radical cystectomy in locally advanced muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized trials. Investigative and Clinical Urology, 2019, 60, 64. | 1.0 | 12 |
| 304 | Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience. World Journal of Urology, 2019, 37, 2409-2418. | 1.2 | 6 |
| 305 | Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes. European Urology Oncology, 2019, 2, 390-396. | 2.6 | 49 |
| 306 | Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3aN0M0 compared to cT2N0M0 bladder cancer. International Journal of Cancer, 2019, 144, 1453-1459. | 2.3 | 26 |
| 307 | Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience. BJU International, 2019, 123, 1011-1019. | 1.3 | 31 |
| 308 | Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. European Urology, 2019, 75, 604-611. | 0.9 | 197 |
| 309 | Impact of serum sodium concentration on survival outcomes in patients with invasive bladder cancer without metastasis treated by cystectomy. International Journal of Urology, 2019, 26, 429-431. | 0.5 | 5 |
| 310 | Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma. Theranostics, 2020, 10, 707-724. | 4.6 | 12 |
| 311 | Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2020, 18, 201-209.e2. | 0.9 | 13 |
| 312 | Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme. European Urology, 2020, 78, 520-530. | 0.9 | 37 |
| 313 | Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer. Frontiers in Oncology, 2020, 10, 568279. | 1.3 | 11 |
| 314 | Perioperative therapies for urological cancers. Japanese Journal of Clinical Oncology, 2020, 50, 357-367. | 0.6 | 3 |
| 315 | Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. Bladder Cancer, 2020, 6, 363-392. | 0.2 | 1 |
| 316 | Management of Muscle-invasive Bladder Cancer in the 2020s: Challenges and Perspectives. European Urology Focus, 2020, 6, 632-638. | 1.6 | 30 |
| 317 | Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: An observational study. PLoS Medicine, 2020, 17, e1003019. | 3.9 | 48 |
| 318 | Effect of adjuvant chemotherapy in locally advanced urothelial carcinoma of the bladder treated with cystectomy. Actas Urológicas Españolas (English Edition), 2020, 44, 94-102. | 0.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 319 | Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 4036-4050. | 0.6 | 11 |
| 320 | RLC score (R status, lymphovascular invasion, C-reactive protein) predicts survival following radical cystectomy for muscle-invasive bladder cancer. <i>Aktuelle Urologie</i> , 2022, 53, 545-551. | 0.3 | 2 |
| 321 | Population-based outcome of muscle-invasive bladder cancer following radical cystectomy: who can benefit from adjuvant chemotherapy?. <i>Translational Andrology and Urology</i> , 2021, 10, 356-373. | 0.6 | 2 |
| 322 | A network pharmacology perspective for deciphering potential mechanisms of action of <i>Solanum nigrum</i> L. in bladder cancer. <i>BMC Complementary Medicine and Therapies</i> , 2021, 21, 45. | 1.2 | 19 |
| 323 | Perioperative therapy in muscle invasive bladder cancer. <i>Indian Journal of Urology</i> , 2021, 37, 226. | 0.2 | 2 |
| 325 | Will the Use of Biomarkers Improve Bladder Cancer Radiotherapy Delivery?. <i>Clinical Oncology</i> , 2021, 33, e264-e273. | 0.6 | 4 |
| 326 | Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma. , 2021, 3, 115-136. | | 2 |
| 327 | Detrimental Effect of Various Preparations of the Human Amniotic Membrane Homogenate on the 2D and 3D Bladder Cancer In vitro Models. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 690358. | 2.0 | 6 |
| 328 | Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 2102-2114. | 13.9 | 427 |
| 329 | Neoadjuvant Chemotherapy Followed by Cystectomy: a Single-Center Experience. <i>Indian Journal of Surgical Oncology</i> , 0, , 1. | 0.3 | 0 |
| 330 | Extranodal Extension Predicts Poor Survival Outcomes among Patients with Bladder Cancer. <i>Cancers</i> , 2021, 13, 4108. | 1.7 | 1 |
| 331 | GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 795-806. | 2.0 | 7 |
| 332 | Harnblasenkarzinom. , 2014, , 415-502. | | 3 |
| 333 | Efecto de la quimioterapia adyuvante en el carcinoma urotelial de vejiga localmente avanzado tratado con cistectomÃa. <i>Actas UrolÃ3gicas EspaÃ±olas</i> , 2020, 44, 94-102. | 0.3 | 1 |
| 334 | Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. <i>PLoS ONE</i> , 2016, 11, e0155503. | 1.1 | 7 |
| 335 | miR-708-5p: a microRNA with emerging roles in cancer. <i>Oncotarget</i> , 2017, 8, 71292-71316. | 0.8 | 49 |
| 336 | Comparison of Efficacy of Adjuvant MEC (Methotrexate, Epirubicin and Cisplatin) and GC (Gemcitabine) Tj ETQq0 0,0 rgBT /Overlock 10 | 0.5 | 6 |
| 337 | Optimal timing of chemotherapy and cystectomy. <i>F1000 Medicine Reports</i> , 2010, 2, . | 2.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 338 | Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. Translational Andrology and Urology, 2015, 4, 273-82. | 0.6 | 4 |
| 339 | Treatment of locally advanced and metastatic bladder cancer. Indian Journal of Urology, 2008, 24, 84. | 0.2 | 5 |
| 340 | Systemic therapy in bladder cancer. Indian Journal of Urology, 2017, 33, 118. | 0.2 | 9 |
| 341 | Long-term results of a single-center prospective randomized trial assessing efficacy of a shortened course of adjuvant chemotherapy after radical cystectomy in patients with locally advanced bladder cancer. Central European Journal of Urology, 2020, 73, 26-32. | 0.2 | 5 |
| 343 | Multidisciplinary Care of Invasive Bladder Cancer: Emerging Roles of Chemotherapy. , 2008, , 361-376. | | 0 |
| 345 | Beyond BCG: Gemcitabine. , 2009, , 115-125. | | 1 |
| 346 | Adjuvant Chemotherapy in Bladder Cancer: A Good Concept But Whereâ€™s the Proof?. , 2009, , 239-245. | | 1 |
| 347 | Therapieschemata in der Uroonkologie. , 2009, , 1-15. | | 0 |
| 349 | Tumorerkrankungen und medikamentÃ¶se Therapie. , 2010, , 3-25. | | 0 |
| 353 | Urothelial Carcinoma: Role of Perioperative Systemic Chemotherapy. , 2012, , 283-292. | | 0 |
| 355 | Management of Metastatic and Invasive Bladder Cancer. , 2012, , 2355-2374.e6. | | 4 |
| 358 | Principles of Bladder Cancer Surgery. , 2014, , 5-25. | | 1 |
| 362 | Epidemiology and Natural History. , 2015, , 3-16. | | 0 |
| 365 | Invasive Bladder Cancer: Combined Modality Treatment. , 2015, , 591-608. | | 0 |
| 366 | Urothelkarzinom der Harnblase: Neoadjuvante und adjuvante medikamentÃ¶se Tumorthherapie. , 2015, , 1-7. | | 0 |
| 367 | Muscle-invasive transitional cell carcinoma of the bladder. , 2015, , 133-142. | | 0 |
| 370 | Neoadjuvant accelerated MVAC therapy in bladder cancer: toxicity and efficacy correlation. American Journal of BioMedicine, 2015, 3, 582-594. | 0.0 | 1 |
| 371 | Urothelkarzinom der Harnblase: Neoadjuvante und adjuvante medikamentÃ¶se Tumorthherapie. , 2016, , 751-755. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 372 | Systemic treatment for bladder cancer. <i>Urologie Pro Praxi</i> , 2016, 17, 102-105. | 0.0 | 1 |
| 373 | Chemotherapy and targeted therapy for bladder cancer. <i>Onkologie (Czech Republic)</i> , 2019, 13, 201-204. | 0.0 | 0 |
| 375 | Chemotherapeutic Agents for Urologic Oncology: Basic Principles. , 2020, , 611-637. | | 0 |
| 376 | ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3. | | 0 |
| 377 | Harnblasenkarzinom. , 2014, , 415-502. | | 0 |
| 380 | Dr. North's rebuttal. <i>Canadian Urological Association Journal</i> , 2008, 2, 228. | 0.3 | 0 |
| 381 | What is the role of adjuvant chemotherapy in locally advanced and lymph node-positive bladder cancer after radical cystectomy?. <i>Indian Journal of Urology</i> , 2009, 25, 281-2. | 0.2 | 0 |
| 382 | Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort. <i>Canadian Urological Association Journal</i> , 2012, 6, E217-23. | 0.3 | 9 |
| 384 | Epidemiology and Hospitalization Cost of Bladder Cancer in Kerman Province, Southeastern Iran. <i>Iranian Journal of Public Health</i> , 2018, 47, 567-574. | 0.3 | 1 |
| 385 | Emodin inhibits the proliferation and invasion of bladder cancer cells via down-regulating Notch1. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 9452-9459. | 0.5 | 3 |
| 386 | Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 543-551. | 0.3 | 6 |
| 387 | Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials. <i>European Urology</i> , 2022, 81, 50-61. | 0.9 | 43 |
| 388 | Urothelkarzinom der Harnblase: Neoadjuvante und adjuvante medikamentöse Tumorthherapie. <i>Springer Reference Medizin</i> , 2021, , 1-5. | 0.0 | 0 |
| 389 | Neoadjuvant chemotherapy for upper tract urothelial carcinoma. <i>Translational Cancer Research</i> , 2020, 9, 6576-6582. | 0.4 | 2 |
| 390 | Biomarkers in muscle invasive bladder cancer. <i>Advances in Clinical Chemistry</i> , 2022, 107, 265-297. | 1.8 | 5 |
| 391 | PARP inhibitors chemopotentiates and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth. <i>BMC Cancer</i> , 2022, 22, 312. | 1.1 | 3 |
| 392 | Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , . | 0.8 | 2 |
| 393 | Non-surgical treatment of bladder cancer. <i>Urologie Pro Praxi</i> , 2020, 21, 102-106. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 395 | Predictive Biomarkers in Muscle Invasive Bladder Cancer: Are We There Yet?. <i>European Urology</i> , 2023, 83, 318-319. | 0.9 | 0 |
| 396 | Adjuvant chemotherapy plus radiotherapy versus chemotherapy alone for locally advanced bladder cancer after radical cystectomy. <i>Bladder Cancer</i> , 2022, , 1-13. | 0.2 | 0 |
| 397 | Oncological Outcomes for Patients Harboring Positive Surgical Margins Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Multicentric Study on Behalf of the YAU Urothelial Group. <i>Cancers</i> , 2022, 14, 5740. | 1.7 | 5 |
| 398 | A risk score for the prognosis prediction of the muscle-invasive bladder cancer patients who received gemcitabine plus cisplatin chemotherapy. <i>Aging</i> , 0, , . | 1.4 | 0 |
| 399 | The influence of serum sodium concentration on prognosis in patients with urothelial carcinoma treated by radical cystectomy. <i>Medicine (United States)</i> , 2022, 101, e31973. | 0.4 | 0 |
| 400 | Neoadjuvant and adjuvant chemotherapy share equivalent efficacy in improving overall survival and cancer-specific survival among muscle invasive bladder cancer patients who undergo radical cystectomy: a retrospective cohort study based on SEER database. <i>Translational Andrology and Urology</i> , 2023, 12, 330-346. | 0.6 | 1 |
| 402 | Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities. <i>European Urology Oncology</i> , 2023, 6, 366-375. | 2.6 | 7 |
| 405 | Urothelkarzinom der Harnblase: Neoadjuvante und adjuvante medikamentöse Tumorthherapie. <i>Springer Reference Medizin</i> , 2023, , 819-823. | 0.0 | 0 |